Immune Repertoire Sequencing Market Companies

The global immune repertoire sequencing (IRS) market is expected to reach USD 560.5 million in 2030 from USD 354.6 million in 2025 at a CAGR of 9.6% during the forecast period. Rapid technological advancements and growing demand for personalized and precision medicines drive market growth. Increasing applications in autoimmune disease research, the growing use of IRS in organ transplant monitoring, and the rising focus on immunotherapy propel market growth. Moreover, the combination of AI and ML, together with growing applications in vaccine development, should open major prospects for market growth. Trade restrictions, regulations, and high capital investment needs present challenges to market growth.

The IRS market is competitive. Key market players include Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), PacBio (US), BGI Group (China), QIAGEN (Germany), 10x Genomics (US), Danaher Corporation (US), Azenta US Inc (US), Oxford Nanopore Technologies plc (UK), Agilent Technologies (US), Takara Bio Inc. (Japan), Tecan Trading AG (Switzerland), Adaptive Biotechnologies (US), Personalis, Inc. (US), and Creative Biolabs (US). These companies have adopted various strategies such as partnerships, contracts, expansions, and acquisitions to strengthen their position in the market. Organic and inorganic strategies have helped the market players expand globally by offering IRS products and services. However, regulatory & trade barriers, along with high capital investments, act as a barrier for new entrants in the market.

To know about the assumptions considered for the study download the pdf brochure

Illumina, Inc. (US) leads the IRS market through platforms such as NovaSeq X and AmpliSeq TCR kits, supported by its BaseSpace bioinformatics tools. The company’s high-throughput solutions enable comprehensive TCR/BCR profiling for IRS. Despite challenges such as high instrument costs and growing competition from long-read sequencing providers, Illumina maintains strong positioning due to global reach, R&D strength, and recent acquisitions, including Fluent BioSciences (July 2024), which enhance its single-cell and multi-omics capabilities.

Thermo Fisher Scientific Inc. (US) offers Ion Torrent platforms and Oncomine assays for immune repertoire workflows, providing end-to-end sequencing solutions from sample prep to analysis. It faces competitive pressure from Illumina in TCR/BCR profiling. The July 2024 acquisition of Olink Holding AB strengthens its proteomics and NGS integration, enhancing immune monitoring capabilities. Strategic expansion and diagnostics-focused development remain key elements of its market presence.

PacBio (US) supports the IRS market through HiFi sequencing systems such as Revio™, enabling highly accurate full-length TCR/BCR analysis. Its long-read technologies support vaccine research and immune monitoring but face adoption hurdles due to cost and throughput limitations. A strategic alliance formed in September 2023 with Hamilton®, Integra®, Revvity™, and Tecan® automates sample preparation and streamlines clinical and biopharma sequencing workflows.

Oxford Nanopore Technologies plc (UK) provides portable, real-time IRS solutions through platforms such as MinION and PromethION, supporting native RNA/DNA sequencing. The company focuses on field-based and clinical applications, with innovations such as direct RNA kits enhancing immune response tracking. In February 2025, it announced certified compatibility with 10x Genomics’ latest single-cell chemistries, strengthening its clinical utility and strategic position in high-accuracy, long-read sequencing.

10x Genomics, Inc. (US) offers the Chromium Single Cell Immune Profiling platform, specializing in high-resolution TCR/BCR diversity analysis at the single-cell level. It serves as a niche provider within the IRS market, targeting applications requiring deep cellular insights. The February 2025 collaboration with Oxford Nanopore integrates GEM-X 3’ and 5’ chemistries with Nanopore’s V14 platform, enhancing multi-platform compatibility for immune repertoire studies.

Market Ranking, 2024

The global IRS market is competitive, with several local, regional, and global players. Various small and medium-sized players operate in both developed and emerging markets, as well as at local and regional levels. The global IRS market is primarily dominated by Illumina, Inc. (US), which accounted for the major share of the market in 2024.

Related Reports:

Immune Repertoire Sequencing Market by Product (Instrument, Software, Assay Kit & Reagent (TCR, BCR Kit)), Technology (Sequencing, Bioinformatics), Service (Data Analysis), Application (Research, Drug Discovery & Development) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com